Daiichi invests in antibody-drug combos | Chemical & Engineering News
Volume 95 Issue 19 | p. 13 | Concentrates
Issue Date: May 8, 2017

Daiichi invests in antibody-drug combos

Department: Business
Keywords: biologics, antibody-drug conjugate, Daiichi Sankyo

Daiichi Sankyo will spend about $135 million to enhance its manufacturing capabilities in Japan for antibody-drug conjugates. ADCs link a cytotoxic molecule to an antibody that binds selectively to a target on cancer cells. The company says the investment, in three of its Japanese plants, will improve its ability to make ADCs for investigational and clinical use. Daiichi is developing six ADCs, including two in Phase I clinical trials.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment